|
US5164410A
(en)
|
1988-01-09 |
1992-11-17 |
Takeda Chemical Industries, Ltd. |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
PH26256A
(en)
|
1988-08-12 |
1992-04-01 |
Fujisawa Pharmaceutical Co |
Oxaspiro [2,5] octane derivative
|
|
US5166172A
(en)
|
1988-09-01 |
1992-11-24 |
Takeda Chemical Industries, Ltd. |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
EP0682020A1
(en)
|
1988-09-01 |
1995-11-15 |
Takeda Chemical Industries, Ltd. |
Fumagillol derivatives useful as angiogenesis inhibitors
|
|
US5180738A
(en)
|
1988-09-01 |
1993-01-19 |
Takeda Chemical Industries |
Fumagillol derivatives and pharmaceutical compositions thereof
|
|
ATE87623T1
(de)
|
1989-03-06 |
1993-04-15 |
Takeda Chemical Industries Ltd |
6-epifumagillole, ihre herstellung und ihre verwendung.
|
|
US5288722A
(en)
|
1989-03-06 |
1994-02-22 |
Takeda Chemical Industries, Ltd. |
6-amino-6-desoxyfumagillols, production and use thereof
|
|
US5290807A
(en)
|
1989-08-10 |
1994-03-01 |
Children's Medical Center Corporation |
Method for regressing angiogenesis using o-substituted fumagillol derivatives
|
|
US6017954A
(en)
|
1989-08-10 |
2000-01-25 |
Children's Medical Center Corp. |
Method of treating tumors using O-substituted fumagillol derivatives
|
|
EP0415294A3
(en)
|
1989-08-31 |
1991-06-12 |
Takeda Chemical Industries, Ltd. |
Cyclohexanol derivatives, production and use thereof
|
|
TW282399B
(enExample)
|
1990-05-25 |
1996-08-01 |
Takeda Pharm Industry Co Ltd |
|
|
US5238950A
(en)
|
1991-12-17 |
1993-08-24 |
Schering Corporation |
Inhibitors of platelet-derived growth factor
|
|
ATE205092T1
(de)
|
1992-01-30 |
2001-09-15 |
Takeda Chemical Industries Ltd |
Verfahren zur herstellung hoch-wasserlöslicher zyklodextrinkomplexe
|
|
EP0602586B1
(en)
|
1992-12-16 |
1997-06-04 |
Takeda Chemical Industries, Ltd. |
Stable pharmaceutical composition of fumagillol derivatives
|
|
UA41446C2
(uk)
|
1995-03-27 |
2001-09-17 |
Санофі - Сінтелабо |
Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
|
|
CA2234401A1
(en)
|
1995-10-11 |
1997-04-17 |
Fujisawa Pharmaceutical Co., Ltd. |
Vascular permeation inhibitor
|
|
EP0799616A1
(en)
|
1996-04-01 |
1997-10-08 |
Takeda Chemical Industries, Ltd. |
Oral composition comprising a fumagillol derivative
|
|
AU3968597A
(en)
|
1996-08-02 |
1998-02-25 |
Children's Medical Center Corporation |
Method of regulating the female reproductive system through angiogenesis inhibitors
|
|
US6281245B1
(en)
|
1996-10-28 |
2001-08-28 |
Versicor, Inc. |
Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
|
|
US7115632B1
(en)
|
1999-05-12 |
2006-10-03 |
G. D. Searle & Co. |
Sulfonyl aryl or heteroaryl hydroxamic acid compounds
|
|
NZ337326A
(en)
|
1997-03-04 |
2001-05-25 |
Monsanto Co |
Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds to inhibit the activity of matrix metalloproteinases
|
|
US6207704B1
(en)
|
1997-06-09 |
2001-03-27 |
Massachusetts Institute Of Technology |
Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
|
|
US6306819B1
(en)
|
1997-10-31 |
2001-10-23 |
Massachusetts Institute Of Technology |
Method for regulating size of vascularized normal tissue
|
|
JP2001526255A
(ja)
|
1997-12-23 |
2001-12-18 |
ワーナー−ランバート・カンパニー |
炎症性疾患およびアテローム性動脈硬化症を治療または予防するチオ尿素およびベンズアミド化合物、組成物並びに方法
|
|
US6242494B1
(en)
|
1998-05-01 |
2001-06-05 |
Abbott Laboratories |
Substituted β-amino acid inhibitors of methionine aminopeptidase-2
|
|
KR100357541B1
(ko)
|
1998-05-15 |
2002-10-18 |
주식회사종근당 |
5-데메톡시 푸마질롤 유도체 및 그 제조방법
|
|
KR100357542B1
(ko)
|
1998-05-15 |
2002-10-18 |
주식회사종근당 |
푸마질롤 유도체 및 그 제조방법
|
|
JP2000116337A
(ja)
|
1998-10-09 |
2000-04-25 |
Nippon Shokuhin Kako Co Ltd |
ペットフード
|
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
|
PL351470A1
(en)
|
1999-04-28 |
2003-04-22 |
Aventis Pharma Gmbh |
Tri-aryl acid derivatives as ppar receptor ligands
|
|
KR100651090B1
(ko)
|
1999-07-15 |
2006-11-29 |
바스프 악티엔게젤샤프트 |
5- 및(또는) 6-치환-2-히드록시벤조산 에스테르의 제조 방법
|
|
EP1223932A4
(en)
|
1999-10-01 |
2003-01-15 |
Smithkline Beecham Corp |
COMPOUNDS AND METHODS
|
|
US20020002152A1
(en)
|
2000-04-14 |
2002-01-03 |
Craig Richard A. |
Hydrazide and alkoxyamide angiogenesis inhibitors
|
|
US6323228B1
(en)
|
2000-09-15 |
2001-11-27 |
Abbott Laboratories |
3-substituted indole angiogenesis inhibitors
|
|
PE20020376A1
(es)
|
2000-09-29 |
2002-05-13 |
Abbott Lab |
Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
|
|
AU3947902A
(en)
|
2000-11-01 |
2002-06-03 |
Praecis Pharm Inc |
Therapeutic agents and methods of use thereof for the modulation of angiogenesis
|
|
US6548477B1
(en)
|
2000-11-01 |
2003-04-15 |
Praecis Pharmaceuticals Inc. |
Therapeutic agents and methods of use thereof for the modulation of angiogenesis
|
|
JP4386639B2
(ja)
|
2000-12-20 |
2009-12-16 |
ブリストル−マイヤーズ スクイブ カンパニー |
セロトニンアゴニストおよびアンタゴニストとしての置換されたピロロキノリン化合物およびピリドキノリン化合物
|
|
EP1379241A1
(en)
|
2001-03-29 |
2004-01-14 |
SmithKline Beecham Corporation |
Compounds and methods
|
|
US20020183242A1
(en)
|
2001-04-11 |
2002-12-05 |
Jack Henkin |
Peptide antiangiogenic drugs
|
|
DE60233420D1
(de)
|
2001-09-27 |
2009-10-01 |
Equispharm Co Ltd |
Fumagillolderivate und verfahren zu deren herstellung
|
|
US6803382B2
(en)
|
2001-11-09 |
2004-10-12 |
Galderma Research & Development, S.N.C. |
Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof
|
|
US7119120B2
(en)
|
2001-12-26 |
2006-10-10 |
Genzyme Corporation |
Phosphate transport inhibitors
|
|
KR100451485B1
(ko)
|
2002-03-28 |
2004-10-06 |
주식회사종근당 |
푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
|
|
US6989392B2
(en)
|
2002-06-18 |
2006-01-24 |
Abbott Laboratories |
2-Aminoquinolines as melanin concentrating hormone receptor antagonists
|
|
US7030262B2
(en)
|
2002-08-06 |
2006-04-18 |
Abbott Laboratories |
3-Amino-2-hydroxyalkanoic acids and their prodrugs
|
|
US20040067266A1
(en)
|
2002-10-07 |
2004-04-08 |
Toppo Frank R. |
Weight loss compound
|
|
US7491718B2
(en)
|
2002-10-08 |
2009-02-17 |
Abbott Laboratories |
Sulfonamides having antiangiogenic and anticancer activity
|
|
US20040157836A1
(en)
|
2002-10-08 |
2004-08-12 |
Comess Kenneth M. |
Sulfonamides having antiangiogenic and anticancer activity
|
|
US20040068012A1
(en)
|
2002-10-08 |
2004-04-08 |
Comess Kenneth M. |
Sulfonamides having antiangiogenic and anticancer activity
|
|
US20040204472A1
(en)
|
2003-03-04 |
2004-10-14 |
Pharmacia Corporation |
Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
|
|
UA84025C2
(en)
|
2003-08-08 |
2008-09-10 |
Янссен Фармацевтика Н.В. |
Normal;heading 1;heading 2;2-(QUINOXALIN-5-YLSULFONYLAMINO)-BENZAMIDE COMPOUNDS AS CCK2 MODULATORS
|
|
PE20050948A1
(es)
|
2003-09-09 |
2005-12-16 |
Japan Tobacco Inc |
Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
|
|
RU2389729C2
(ru)
|
2003-12-22 |
2010-05-20 |
Мемори Фармасьютиклз Корпорейшн |
1н-индазолы, 1, 2-бензизоксазолы и 1, 2-бензизотиазолы, их получение и применение
|
|
EP1699812A2
(en)
|
2003-12-29 |
2006-09-13 |
Praecis Pharmaceuticals Inc. |
Inhibitors of methionine aminopeptidase-2 and uses thereof
|
|
KR100552043B1
(ko)
|
2004-02-28 |
2006-02-20 |
주식회사종근당 |
푸마질롤 유도체를 포함하는 비만치료용 조성물
|
|
AU2005245401A1
(en)
|
2004-05-12 |
2005-12-01 |
Chemocentryx |
Aryl sulfonamides
|
|
JP2008505176A
(ja)
|
2004-06-30 |
2008-02-21 |
コンビナトアールエックス インコーポレーティッド |
代謝障害を治療するための方法および試薬
|
|
US20060045865A1
(en)
|
2004-08-27 |
2006-03-02 |
Spherics, Inc. |
Controlled regional oral delivery
|
|
JP2008514608A
(ja)
|
2004-09-24 |
2008-05-08 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
スルホンアミド化合物
|
|
JP2008528574A
(ja)
|
2005-01-26 |
2008-07-31 |
チョン クン ダン ファーマシューティカル コープ． |
フマギロール誘導体またはフマギロール誘導体の製造方法およびこれを含む医薬用組成物
|
|
FR2886855B1
(fr)
|
2005-06-08 |
2009-07-17 |
Agronomique Inst Nat Rech |
Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
|
|
WO2006138475A2
(en)
|
2005-06-16 |
2006-12-28 |
Jenrin Discovery |
Mao-b inhibitors useful for treating obesity
|
|
EA200870117A1
(ru)
|
2005-12-23 |
2008-12-30 |
Смитклайн Бичам Корпорейшн |
Азаиндоловые ингибиторы аурора-киназ
|
|
US20100234364A1
(en)
|
2006-07-14 |
2010-09-16 |
Arindrajit Basak |
Ccr2 inhibitors and methods of use thereof
|
|
DE102007020492A1
(de)
|
2007-04-30 |
2008-11-06 |
Grünenthal GmbH |
Substituierte Sulfonamid-Derivate
|
|
JP2010531896A
(ja)
|
2007-06-26 |
2010-09-30 |
チルドレンズ メディカル センター コーポレーション |
治療的投与のためのＭｅｔＡＰ−２阻害剤ポリマーソーム
|
|
US20090011994A1
(en)
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
|
BRPI0820229A2
(pt)
|
2007-11-28 |
2017-05-09 |
A Stevenson Cheri |
conjugados de análogos de fumagilina biodegradáveis biocompatíveis
|
|
CN101932577B
(zh)
|
2007-11-30 |
2013-07-17 |
拜耳知识产权有限责任公司 |
杂芳基取代的哌啶
|
|
CA2731020A1
(en)
|
2008-07-18 |
2010-01-21 |
Zafgen, Inc. |
Use of antiangiogenic fumagillins in the treatment of obesity
|
|
CN102239149B
(zh)
|
2008-10-06 |
2015-05-13 |
约翰·霍普金斯大学 |
喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法
|
|
WO2010048499A1
(en)
|
2008-10-24 |
2010-04-29 |
Wake Forest University |
Platinum acridine anti-cancer compounds and methods thereof
|
|
US8642650B2
(en)
*
|
2008-12-04 |
2014-02-04 |
Zafgen, Inc. |
Methods of treating an overweight or obese subject
|
|
WO2010065881A2
(en)
|
2008-12-04 |
2010-06-10 |
Zafgen Corporation |
Methods of treating an overweight or obese subject
|
|
US20120004162A1
(en)
|
2008-12-04 |
2012-01-05 |
Vath James E |
Methods of Treating an Overweight or Obese Subject
|
|
US20120010290A1
(en)
|
2008-12-04 |
2012-01-12 |
Vath James E |
Methods of Treating an Overweight or Obese Subject
|
|
MX337575B
(es)
*
|
2009-10-09 |
2016-03-10 |
Zafgen Corp |
Compuestos de sulfona y métodos para lafabricación y uso de éstos.
|
|
US8815309B2
(en)
|
2010-01-08 |
2014-08-26 |
Zafgen, Inc. |
Methods of treating a subject with benign prostate hyperplasia
|
|
US20130023513A1
(en)
|
2010-01-12 |
2013-01-24 |
Hughes Thomas E |
Methods and Compositions for Treating Cardiovascular Disorders
|
|
WO2011150338A1
(en)
|
2010-05-27 |
2011-12-01 |
Zafgen Corporation |
Methods of treating obesity
|
|
US20120020647A1
(en)
|
2010-07-21 |
2012-01-26 |
Rovi Technologies Corporation |
Filtering repeated content
|
|
AU2011281037B2
(en)
|
2010-07-22 |
2014-11-27 |
Zafgen, Inc. |
Tricyclic compounds and methods of making and using same
|
|
US8428080B2
(en)
|
2010-09-16 |
2013-04-23 |
Apple Inc. |
Method to control reconfiguration of multiple radio access bearers in a wireless device
|
|
MX339201B
(es)
|
2010-10-12 |
2016-05-13 |
Zafgen Inc |
Compuestos de sulfonamida y métodos para elaborarlos y usarlos.
|
|
PH12013500934A1
(en)
|
2010-11-09 |
2022-10-24 |
Zafgen Inc |
Crystalline solids of a metap-2 inhibitor and methods of making and using same
|
|
WO2012064928A1
(en)
|
2010-11-10 |
2012-05-18 |
Zafgen Corporation |
Methods and compositions for treating thyroid hormone related disorders
|
|
US20130316994A1
(en)
|
2010-11-29 |
2013-11-28 |
Zafgen, Inc. |
Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
|
|
WO2012103333A1
(en)
|
2011-01-26 |
2012-08-02 |
Zafgen Corporation |
Tetrazole compounds and methods of making and using same
|
|
US9242997B2
(en)
|
2011-05-06 |
2016-01-26 |
Zafgen, Inc. |
Tricyclic pyrazole sulphonamide compunds and methods of making and using same
|
|
CN103748094B
(zh)
|
2011-05-06 |
2016-06-29 |
扎夫根股份有限公司 |
三环磺酰胺化合物及其制备和使用方法
|
|
SG194812A1
(en)
*
|
2011-05-06 |
2013-12-30 |
Zafgen Inc |
Partially saturated tricyclic compounds and methods of making and using same
|
|
WO2013033430A1
(en)
|
2011-09-02 |
2013-03-07 |
Wake Forest School Of Medicine |
Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
|
|
KR20150079952A
(ko)
|
2012-11-05 |
2015-07-08 |
자프겐 인크. |
트리시클릭 화합물 및 그의 제조 및 사용 방법
|
|
MX2015005733A
(es)
|
2012-11-05 |
2016-02-10 |
Zafgen Inc |
Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
|